128 related articles for article (PubMed ID: 34007719)
1. Information or Evidence? Abandoning Imaginary Worlds for Blockchains in Health Technology Assessment.
Langley PC
Innov Pharm; 2018; 9(3):1-5. PubMed ID: 34007719
[TBL] [Abstract][Full Text] [Related]
2. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
[TBL] [Abstract][Full Text] [Related]
3. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
[TBL] [Abstract][Full Text] [Related]
4. Blockchains, Formulary Evaluations and Health Technology Assessment.
Langley PC; Martin RE
Innov Pharm; 2018; 9(4):. PubMed ID: 34007722
[TBL] [Abstract][Full Text] [Related]
5. ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.
Langley PC
Innov Pharm; 2019; 10(4):. PubMed ID: 34007578
[TBL] [Abstract][Full Text] [Related]
6. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
Langley PC
Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
[TBL] [Abstract][Full Text] [Related]
7. Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy.
Langley PC
Innov Pharm; 2019; 10(3):. PubMed ID: 34007562
[TBL] [Abstract][Full Text] [Related]
8. CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER).
Langley PC
Innov Pharm; 2018; 9(4):. PubMed ID: 34007726
[TBL] [Abstract][Full Text] [Related]
9. The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment.
Langley PC
Pharmacy (Basel); 2020 Jul; 8(3):. PubMed ID: 32668706
[TBL] [Abstract][Full Text] [Related]
10. Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds.
Langley PC
Innov Pharm; 2018; 9(2):1-5. PubMed ID: 34007702
[TBL] [Abstract][Full Text] [Related]
11. Facilitating bias in cost-effectiveness analysis: CHEERS 2022 and the creation of assumption-driven imaginary value claims in health technology assessment.
Langley P
F1000Res; 2022; 11():993. PubMed ID: 36226039
[TBL] [Abstract][Full Text] [Related]
12. Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience.
Langley PC
Innov Pharm; 2021; 12(1):. PubMed ID: 34007666
[TBL] [Abstract][Full Text] [Related]
13. Nothing to Cheer About: Endorsing Imaginary Economic Evaluations and Value Claims with CHEERS 22.
Langley P
F1000Res; 2022; 11():248. PubMed ID: 35444797
[TBL] [Abstract][Full Text] [Related]
14. More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.
Langley PC
Innov Pharm; 2020; 11(2):. PubMed ID: 34007618
[TBL] [Abstract][Full Text] [Related]
15. Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.
Langley PC
Innov Pharm; 2020; 11(4):. PubMed ID: 34007644
[TBL] [Abstract][Full Text] [Related]
16. The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies.
Langley PC
Innov Pharm; 2019; 10(3):. PubMed ID: 34007563
[TBL] [Abstract][Full Text] [Related]
17. More Unnecessary Imaginary Worlds - Part 3: Cystic Fibrosis and the Institute for Clinical and Economic Review's Draft Evidence Report.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017638
[TBL] [Abstract][Full Text] [Related]
18. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.
Langley PC
Innov Pharm; 2021; 12(3):. PubMed ID: 35601587
[TBL] [Abstract][Full Text] [Related]
19. Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.
Langley PC
Innov Pharm; 2019; 10(4):. PubMed ID: 34007580
[TBL] [Abstract][Full Text] [Related]
20. Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare Disease.
Langley PC
Innov Pharm; 2022; 13(3):. PubMed ID: 36627905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
